These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20085070)

  • 21. Utility of ezetimibe.
    Ashikaga H; Blumenthal RS; Jones SR
    Am J Cardiol; 2009 May; 103(9):1321-2. PubMed ID: 19406279
    [No Abstract]   [Full Text] [Related]  

  • 22. High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: effects on vascular biomarkers.
    Ferreira CE; França CN; Izar MC; Camargo LM; Roman RM; Fonseca FA
    Int J Cardiol; 2015 Feb; 180():78-9. PubMed ID: 25438220
    [No Abstract]   [Full Text] [Related]  

  • 23. Niacin compared with ezetimibe.
    Weiss SH
    N Engl J Med; 2010 Mar; 362(11):1047; author reply 1048. PubMed ID: 20301797
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niacin compared with ezetimibe.
    Lindsay AC; Halcox JP
    N Engl J Med; 2010 Mar; 362(11):1046; author reply 1048. PubMed ID: 20237352
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of mixed hyperlipidaemia.
    Stalenhoef AF
    Eur Heart J; 2005 May; 26(9):856-7. PubMed ID: 15781431
    [No Abstract]   [Full Text] [Related]  

  • 28. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
    Kłosiewicz-Latoszek L; Cybulska B
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
    [No Abstract]   [Full Text] [Related]  

  • 30. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
    Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM
    Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
    McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
    J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Heart Protection Study].
    Larsen ML; Hildebrandt PR
    Ugeskr Laeger; 2002 Jan; 164(3):348. PubMed ID: 11816337
    [No Abstract]   [Full Text] [Related]  

  • 34. Achieving cholesterol goals. Current and future drug therapies.
    Jones PH
    Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In brief: adding ezetimibe to a statin improves clinical outcomes.
    Med Lett Drugs Ther; 2014; 56(1457):126. PubMed ID: 25461232
    [No Abstract]   [Full Text] [Related]  

  • 36. Ezetimibe added to statin therapy (EASY study) - an evaluation by Australian general practitioners.
    Simons LA; Symons J
    Aust Fam Physician; 2007; 36(1-2):90-2, 96. PubMed ID: 17252094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of ezetimibe in clinical practice.
    Jurado J; Seip R; Thompson PD
    Am J Cardiol; 2004 Mar; 93(5):641-3. PubMed ID: 14996600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [How sure is the combined lipid lowering?].
    Schäfer J
    MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.